Cdk7-flox Mouse

Cdk7, or cyclin-dependent kinase 7, is a crucial protein. Along with cyclin H and MAT1, it forms the CDK-activating complex (CAK) that phosphorylates cell cycle CDKs for cell cycle progression. As a component of the general transcription factor TFIIH, Cdk7-mediated phosphorylation of RNA polymerase II at active gene promoters enables transcription [1,5].

In multiple myeloma, Cdk7 expression positively correlates with E2F and MYC transcriptional programs. Its inhibition counteracts E2F activity, impairs MYC-regulated metabolic gene signatures, and causes in vivo tumor regression [2].

In small cell lung cancer, inhibiting Cdk7 disrupts cell-cycle progression, induces DNA replication stress and genome instability, and triggers an immune-response signaling, providing a rationale for combination regimens with immunotherapies [4].

In esophageal squamous cell carcinoma, the CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties [3].

In conclusion, Cdk7 is a key regulator in cell cycle and gene transcription. Its inhibition shows potential in treating various cancers including multiple myeloma, small cell lung cancer, and esophageal squamous cell carcinoma. Studies using in vivo models have revealed its roles in tumor-related biological processes, highlighting its significance as a therapeutic target in cancer research.